表紙
市場調查報告書
商品編碼
1026606

非酒精性脂肪性肝炎(NASH):全球臨床試驗檢討(2021年下半年)

Non-Alcoholic Steatohepatitis (NASH) - Global Clinical Trials Review, 2022

出版日期: | 出版商: GlobalData | 英文 561 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供非酒精性脂肪性肝炎(NASH)的相關調查,提供世界主要國家中進行的臨床試驗數及其平均登記數概要,主要企業評估,刊載各地區·階段·臨床試驗現狀·端點現狀·贊助商類型的臨床試驗,臨床試驗進行中的藥物,過去5年的登記趨勢等資料。

目錄

目錄

表格清單

圖清單

  • 報告指南
  • 臨床試驗調查範圍
  • 各地區的臨床試驗
  • 各國臨床試驗與平均登記
  • 亞太地區有助於臨床試驗的主要5個國家
  • 歐洲有助於臨床試驗的主要5個國家
  • 北美有助於臨床試驗的主要國家
  • 中東和非洲有助於臨床試驗的主要5個國家
  • 中南美有助於臨床試驗的主要5個國家
  • G7各國:腸胃臨床試驗上非酒精性脂肪性肝炎(NASH)的比例
  • 不同階段:G7各國的臨床試驗
  • 各臨床試驗狀態:G7各國的臨床試驗
  • E7各國:腸胃臨床試驗上非酒精性脂肪性肝炎(NASH)的比例
  • 不同階段:E7各國的臨床試驗
  • 各臨床試驗狀態:E7各國的臨床試驗
  • 各期臨床試驗
  • 各期進行中的臨床試驗
  • 各臨床試驗狀態的臨床試驗
  • 各端點狀態的臨床試驗
  • 一定期間所募集的實驗對象
  • 各贊助商類型的臨床試驗
  • 主要贊助商
  • 參加治療藥物臨床實驗的主要企業
  • 主要藥物
  • 臨床試驗簡介的概述

附錄

  • 簡稱
  • 定義
  • 調查手法
  • 2次調查
  • 關於GlobalData
  • 諮詢方式
  • 資訊來源
目錄
Product Code: GDHC6845CTIDB

GlobalData's clinical trial report, "Non-Alcoholic Steatohepatitis (NASH) - Global Clinical Trials Review, 2022" provides an overview of Non-Alcoholic Steatohepatitis (NASH) Clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis (NASH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

  • Report Guidance
  • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Clinical Trials by G7 Countries: Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots

Appendix

  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About GlobalData
  • Contact Us
  • Source

List of Tables

List of Tables

  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Region, 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Europe, Top Five Countries, 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, North America, Top Countries, 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2022*
  • Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials, G7 Countries (%), 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, G7 Countries, Clinical Trials by Phase, 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2022*
  • Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials, E7 Countries (%), 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, E7 Countries, Clinical Trials by Phase, 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Phase, 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials In Progress by Phase 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Trial Status, 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, by End Point Status, 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2017-2021
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Key Sponsors, 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2022*

List of Figures

List of Figures

  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Region (%), 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, North America, Top Countries (%), 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2022*
  • Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials, G7 Countries (%), 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, G7 Countries, Clinical Trials by Phase, 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2022*
  • Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials, E7 Countries (%), 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, E7 Countries, Clinical Trials by Phase, 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Phase (%), 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials In Progress by Phase, 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Trial Status, 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, by End Point Status, 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2017-2021
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Key Sponsors, 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2022*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2022*
  • GlobalData Methodology